Climb Bio, Inc. (CLYM)
NGM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Climb Bio, Inc.
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -10.7M | -14.9M | -19.3M | -15.2M |
| Net Income | -8.7M | -12.9M | -17.5M | -13.7M |
| Diluted EPS | $-0.13 | $-0.19 | $-0.26 | $-0.20 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -45.1M | -40.3M | -30.4M | -67.9M |
| Net Income | -45.2M | -35.1M | -73.9M | -59.9M |
| Diluted EPS | $-1.72 | $-1.30 | $-1.53 | $-0.88 |